SOURCE: Generex Biotechnology

April 11, 2007 08:00 ET

Generex Biotechnology to Make Presentations at the American Association of Clinical Endocrinologists 16th Annual Meeting & Clinical Congress

TORONTO -- (MARKET WIRE) -- April 11, 2007 -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that it will be making two poster presentations at the American Association of Clinical Endocrinologists (AACE) 16th Annual Meeting & Clinical Congress ( in Seattle, Washington, April 11 - 15, 2007.

The Company will be making the following poster presentations:

--  Oral Insulin (Generex Oral-lyn™) 6-Month Lunchtime Replacement in
    Juvenile Type-1 DM, by Doctors Jaime Guevara-Aguirre, Marco Guevara-
    Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology
    IEMYR, Quito, Ecuador.
--  Regular Insulin Replacement by Oral Insulin at Mealtime in Type-1 DM,
    by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette
    Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador.
AACE is a professional community of Clinical Endocrinologists that is committed to transforming the lives of patients by enabling one another to practice leading edge, proactive, ethical and cost-effective medicine. Members of AACE are physicians with special education, training and interest in the practice of clinical endocrinology. These physicians devote a significant part of their career to the evaluation and management of patients with endocrine disease. All members of AACE are physicians (M.D. or D.O.) and a majority is certified by Boards recognized by the American Board of Medical Specialties. Members of AACE are recognized clinicians, educators and scientists, many of whom are affiliated with medical schools and universities. Members of AACE contribute on a regular and continuing basis to the scientific literature on endocrine diseases and conduct medical education programs on this subject.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact Information

  • For more information, please contact:

    For Generex:
    Shayne Gilliatt

    Andrew Hellman
    CEOcast, Inc.